TG Therapeutics jumps after Q4 rev tops estimates

TG Therapeutics

28/02/2024 18:51

** Shares of TG Therapeutics  TGTX.O  rise 26% to $17.53  
    ** TGTX posts total Q4 rev of $43.97 million vs analysts'
average estimates of $40.06 mln - LSEG data 
    ** Co maintains 2024 sales outlook for its multiple
sclerosis (MS) drug, Briumvi, in the range of $220 million to
$260 million
    ** Analysts on average expect Briumvi sales of $248.05 mln
for 2024 -LSEG data 
     ** U.S. FDA approved Briumvi, a monoclonal antibody used
for the treatment of patients with relapsing forms of MS, in
2022
    ** MS is a neurological disease which causes the immune
system to attack brain cells, causing motor disabilities
    ** Including session gains, stock up 9.4% in the last 12
months

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))